Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.
Medical education must acknowledge the problematic use of race as a biological or epidemiological risk factor in research and the controversy over race.
AMA J Ethics. 2017;19(6):518-527. doi:
10.1001/journalofethics.2017.19.6.peer1-1706.
The Moseley study found no significant difference between those in the arthroscopic lavage and debridement arm of the study and those in the sham surgery arm.
The NRMP’s new “all-in” policy requires every residency program to fill every first-year position either exclusively through the match or outside of it. Programs that continue to offer prematches will operate outside the match.
Hilary Daniel joins Ethics Talk to discuss her article, coauthored with Courtney Perlino and Dr Amy B. Cadwallader: “Which Drugs Should Be on the Essential Medicines List?”
Thomas W. LeBlanc, MD, MA and Amy P. Abernethy, MD, PhD
One strategy to promote adherence is the use of “care pathways,” effectively roadmaps that seek to standardize cancer treatment on the basis of some agreed-upon set of guidelines within a particular center or group of patients.